Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year

Abstract

Aims: Dapagliflozin and exenatide reduce body weight by differing mechanisms. Dual therapy with these agents reduces body weight, adipose tissue volume, glycaemia and systolic blood pressure (SBP) over 24 weeks. Here, we examined these effects over 1 year in obese adults without diabetes.

Materials and methods: Obese adults without diabetes (N = 50; aged 18-70 years; body mass index, 30-45 kg/m2 ) were initially randomized to double-blind oral dapagliflozin 10 mg once daily plus subcutaneous long-acting exenatide 2 mg once weekly or to placebo. They entered an open-label extension from 24 to 52 weeks during which all participants received active treatment.

Results: Of the original 25 dapagliflozin + exenatide-treated and 25 placebo-treated participants, respectively, 21 (84%) and 17 (68%) entered the open-label period and 16 (64%) and 17 (68%) completed 52 weeks of treatment. At baseline, mean body weight was 104.6 kg, and 73.5% of participants had prediabetes (impaired fasting glucose or impaired glucose tolerance). Reductions with dapagliflozin + exenatide at 24 weeks were sustained at 52 weeks, respectively, for body weight (-4.5 and -5.7 kg), total adipose tissue volume (-3.8 and -5.3 L), proportion with prediabetes (34.8% and 35.3%), and SBP (-9.8 and -12.0 mm Hg). Effects on body weight, SBP and glycaemia at 52 weeks with placebo → dapagliflozin + exenatide were similar to those observed with continuation of dapagliflozin + exenatide. Nausea and injection-site reactions were more frequent with dapagliflozin + exenatide than with placebo and diminished over time. Safety and tolerability were similar to that in previous diabetes trials with these agents. No clear difference in adverse event-related withdrawals between placebo and active treatment periods was observed.

Conclusions: Dapagliflozin + exenatide dual therapy produced sustained reductions in body weight, prediabetes and SBP over 52 weeks and was well tolerated in obese adults without diabetes.

Keywords: dapagliflozin; exenatide; obesity; prediabetes.

© 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Figures

Figure 1

A, Study design and B, CONSORT flow diagram. DAPA + ExQW, dapagliflozin 10 mg once daily plus exenatide 2 mg once weekly; ITT, intention to treat; PBO, placebo; QD, once daily; QW, once weekly. *A profound lifestyle change, including a strict low‐carbohydrate/high‐fat diet that elevated blood ketones. This resulted in withdrawal of this patient during blinded study phase and exclusion of this patient from the full analysis set

Figure 2

Changes in body weight, body composition, abdominal adipose tissue, and SBP. A, Primary endpoint: adjusted mean change from week 0 in body weight (kg) at 24 and 52 weeks. B, Secondary endpoint: adjusted mean percentage change from week 0 in body weight (%) at 24 and 52 weeks. C, Individual participant trajectories of percent change in body weight over 52 weeks in dapagliflozin/exenatide‐treated participants (*although 9 participants discontinued DAPA + ExQW, 1 of these participants attended the final visit for weight measurement). D, Corresponding trajectories in placebo‐treated participants. E, Adjusted mean change from week 0 in total lean and total adipose tissue volume and in visceral subcutaneous adipose tissue volume at 24 and 52 weeks among participants continuing on DAPA + ExQW throughout the study. F, Adjusted mean change from week 0 in SBP (mm Hg) over 24 and 52 weeks. Analyses in panels A, B, E and F employed mixed models for repeated measures of change or percentage change from baseline adjusted for treatment, week, treatment‐by‐week, sex and baseline value. CI, confidence interval; DAPA + ExQW, dapagliflozin 10 mg once daily plus exenatide 2 mg once weekly; PBO, placebo; SBP, systolic blood pressure; w, week(s)

Figure 3

Changes in glycaemic endpoints and prediabetes. A, Adjusted mean change from week 0 in HbA1c (mmol/mol) over 24 and 52 weeks. B, Adjusted mean change from week 0 in FPG (mmol/L) after 24 and 52 weeks. C, Proportion of participants in the original DAPA + ExQW group with impaired fasting glucose or impaired glucose tolerance at screening and after 24 and 52 weeks. Analyses in panels A and B employed mixed models for repeated measures of change or percentage change from baseline adjusted for treatment, week, treatment‐by‐week, sex and baseline value. CI, confidence interval; DAPA + ExQW, dapagliflozin 10 mg once daily plus exenatide 2 mg once weekly; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; PBO, placebo; w, week(s). *Two participants for whom values were missing. †Eight participants for whom values were missing. ‡Ten participants for whom values were missing